NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=140991&from=4CLASS PERIOD: March 13, 2023 to March 11, 202 ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 19, 2025 [2][4]. Group 1: Allegations Against Zynex - The complaint alleges that Zynex and its executives made false or misleading statements and failed to disclose critical information, including shipping excess products, inflating revenue, and facing scrutiny from insurers like Tricare [4]. - A report published by medical journal STAT accused Zynex of an "oversupplying scheme," leading to insurers removing the company from their networks [5]. - Following the report, Zynex's stock price dropped by $0.50 per share, or 5%, closing at $9.35 on June 4, 2024, amid heavy trading volume [5]. Group 2: Financial Performance and Market Reaction - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers and a temporary suspension of payments from Tricare [6]. - The announcement led to a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51.3%, closing at $3.41 on March 12, 2025, also on unusually heavy trading volume [7].

Core Message - Zynex Inc is focused on providing noninvasive, non-addictive at-home pain management solutions through its flagship device, NexWave, addressing the opioid crisis by offering alternative pain management options for healthcare providers and patients [1][5]. Company Overview - Zynex Medical's mission is to combat the opioid crisis by offering alternatives for pain management, which aligns with the company's culture and growth strategy [4][9]. - The company has nearly 300 sales representatives across the U.S. dedicated to educating healthcare providers about non-opioid pain management options [5]. Product Details - NexWave is a 3-in-1 device that incorporates TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation), making it versatile for rehabilitation and pain management [6]. - The device is designed to be user-friendly and effective, particularly for muscle re-education and post-operative care [6]. Growth Strategy - The company has experienced significant growth and aims to expand its reach by educating more healthcare providers and increasing brand awareness [7]. - Current growth efforts are primarily focused on the U.S. market, which presents substantial opportunities for outreach and education [8]. Demographic Alignment - With an aging population increasingly seeking non-surgical pain management solutions, Zynex's offerings are well-positioned to meet this demand, particularly among elderly patients who are looking for non-opioid alternatives [10].

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. for alleged securities fraud affecting investors between March 13, 2023, and March 11, 2025 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover losses for Zynex, Inc. investors adversely affected by alleged securities fraud during the specified period [1]. Case Details - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2]. - It is claimed that the company's practice of filing false claims attracted scrutiny from insurers, including the U.S. military health insurance program, Tricare [2]. - The lawsuit suggests that Zynex may face adverse consequences such as removal from insurer networks and federal penalties due to these practices [2]. - Defendants' positive statements regarding the company's business and prospects are alleged to be materially misleading and lacking a reasonable basis [2]. Next Steps - Investors who suffered losses in Zynex, Inc. during the relevant timeframe have until May 19, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Why Levi & Korsinsky - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the “Class Period”), of the important May 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI). Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=140443&from=3 CLASS PERIOD: March 13, 2023 to Marc ...

NEW YORK, April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=140408&from=4CLASS PERIOD: March 13, 2023 to March 11, 202 ...

ZYXI Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO , April 2, 2025 /PRNewswire/ -- A securities class action has been filed against Zynex, Inc. (NASDAQ: ZYXI), a medical device manufacturer that produces and markets electrotherapy devices for use in pain management and physical rehabilitation, after it reported dismal Q4 and FY 2024 financial results which sent the price of Zynex shares down $3.59 (-51%) on March 12, 2025. The suit, captioned Tuncel v. Zynex, Inc., et al., No. 1:25-cv-00 ...

ZYXI investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the l ...

NEW YORK, April 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-f ...